Nanexa AB announces that the phase I study with NEX-22, the company's one-month formulation of liraglutide, will resume with further dose escalation with an expected start in the first quarter of 2025 ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

SLOWLY lifting her head off her sweat-drenched pillow, Aisleyne Horgan-Wallace vomits into the sick bucket next to her bed. ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger ...